Correlation of Epstein-Barr virus-specific cytotoxic T lymphocyte precursors (EBV-CTLp) after tabelecleucel with response and survival in rituximab relapsing or refractory EBV+ post-transplant lymphoproliferative disease (PTLD).

Blake T. Aftab,Rhine R. Shen,Norma Guzman-Becerra,Yan Sun,Farahnaz Forozan,Susan E. Prockop,Ekaterina Doubrovina,Richard J. O’Reilly,Xiaoming Li,Minoti Hiremath,Laurence Gamelin,Willis H. Navarro

Correlation of Epstein-Barr virus-specific cytotoxic T lymphocyte precursors (EBV-CTLp) after tabelecleucel with response and survival in rituximab relapsing or refractory EBV+ post-transplant lymphoproliferative disease (PTLD).

2020

Blake T. Aftab
Rhine R. Shen
Norma Guzman-Becerra
Yan Sun
Farahnaz Forozan
Susan E. Prockop
Ekaterina Doubrovina
Richard J. O’Reilly
Xiaoming Li
Minoti Hiremath
Laurence Gamelin
Willis H. Navarro

38Background: EBV+ PTLD is often a fatal disease. Tabelecleucel is an investigational off-the-shelf, allogeneic T-cell immunotherapy specific for EBV antigens. Functional in vivo expansion approxim...

Keywords:

Rituximab
Lymphoproliferative disease
In vivo
Epstein–Barr virus
Immunology
Cytotoxic T cell
Medicine
Immunotherapy
Antigen
Pathology
Refractory
post transplant

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations